|
🐜
|
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
18 auth.
R. Orlowski,
T. Stinchcombe,
B. Mitchell,
T. Shea,
A. Baldwin,
S. Stahl,
J. Adams,
D. Esseltine,
P. Elliott,
C. Pien,
...
R. Guerciolini,
Jessica Anderson,
N. Depcik-Smith,
R. Bhagat,
M. Lehman,
S. Novick,
O. O’Connor,
S. Soignet
|
9 |
2002 |
9
🐜
|
|
🐜
|
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
17 auth.
W. Wilson,
O. O’Connor,
M. Czuczman,
A. LaCasce,
J. Gerecitano,
J. Leonard,
A. Tulpule,
K. Dunleavy,
H. Xiong,
Y. Chiu,
...
Yue Cui,
T. Busman,
S. Elmore,
S. Rosenberg,
A. Krivoshik,
S. Enschede,
R. Humerickhouse
|
9 |
2010 |
9
🐜
|
|
🐜
|
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
15 auth.
R. Fisher,
S. Bernstein,
B. Kahl,
B. Djulbegovic,
M. Robertson,
S. de Vos,
E. Epner,
A. Krishnan,
J. Leonard,
S. Lonial,
...
E. Stadtmauer,
O. O’Connor,
Hongliang Shi,
A. Boral,
A. Goy
|
9 |
2006 |
9
🐜
|
|
🐜
|
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
16 auth.
W. Kelly,
V. Richon,
O. O’Connor,
T. Curley,
Barbara MacGregor-Curtelli,
W. Tong,
M. Klang,
L. Schwartz,
S. Richardson,
E. Rosa,
...
M. Drobnjak,
C. Cordon-Cordo,
J. Chiao,
R. Rifkind,
P. Marks,
H. Scher
|
9 |
2003 |
9
🐜
|
|
🦁
|
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
20 auth.
O. O’Connor,
B. Pro,
L. Pinter-Brown,
N. Bartlett,
L. Popplewell,
B. Coiffier,
M. Lechowicz,
K. Savage,
A. Shustov,
C. Gisselbrecht,
...
E. Jacobsen,
P. Zinzani,
R. Furman,
A. Goy,
C. Haioun,
M. Crump,
J. Zain,
E. Hsi,
A. Boyd,
S. Horwitz
|
9 |
2011 |
9
🦁
|
|
🦁
|
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
16 auth.
O. O’Connor,
J. Wright,
C. Moskowitz,
J. Muzzy,
Barbara Macgregor-Cortelli,
M. Stubblefield,
D. Straus,
C. Portlock,
P. Hamlin,
Elizabeth Choi,
...
Otila Dumetrescu,
D. Esseltine,
E. Trehu,
J. Adams,
D. Schenkein,
A. Zelenetz
|
9 |
2005 |
9
🦁
|
|
🐜
|
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
150 auth.
S. Horwitz,
O. O’Connor,
B. Pro,
T. Illidge,
M. Fanale,
R. Advani,
N. Bartlett,
J. H. Christensen,
F. Morschhauser,
E. Domingo-Domènech,
G. Rossi,
W. Kim,
T. Feldman,
A. Lennard,
D. Belada,
...
Á. Illés,
K. Tobinai,
K. Tsukasaki,
S. Yeh,
A. Shustov,
A. Hüttmann,
K. Savage,
S. Yuen,
S. Iyer,
P. Zinzani,
Zhaowei Hua,
M. Little,
Shangbang Rao,
J. Woolery,
T. Manley,
L. Trümper,
D. Aboulafia,
O. Alpdogan,
K. Ando,
L. Arcaini,
L. Baldini,
Naresh Bellam,
N. Bartlett,
D. B. Yehuda,
F. Benedetti,
Peter Borchman,
D. Bordessoule,
P. Brice,
J. Briones,
D. Caballero,
A. Carella,
Hung Chang,
June Weon Cheong,
Seok-Goo Cho,
I. Choi,
S. Choquet,
A. Colita,
Angela Giovanna Congui,
F. d'Amore,
N. Dang,
K. Davison,
S. Guibert,
P. Brown,
V. Delwail,
J. Demeter,
F. Raimondo,
Y. Do,
E. Domingo,
Michael G. Douvas,
M. Dreyling,
T. Ernst,
K. Fay,
S. Ferrero,
I. Flinn,
A. Forero-Torres,
C. Fox,
J. Friedberg,
N. Fukuhara,
J. García-Marco,
Jorge Gayoso Cruz,
J. Codina,
R. Gressin,
A. Grigg,
R. Gurion,
C. Haioun,
R. Hájek,
M. Hanel,
K. Hatake,
Rob Hensen,
N. Horowitz,
A. Huttmann,
Á. Illés,
K. Ishizawa,
M. Islas‐Ohlmayer,
E. Jacobsen,
M. Janakiram,
W. Jurczak,
M. Kaminski,
Koji Kato,
I. Kirgner,
C. Kuo,
M. Lazaroiu,
K. Du,
Jong-Seok Lee,
S. Legouill,
P. LaRosée,
I. Levi,
B. Link,
H. Maisonneuve,
D. Maruyama,
J. Mayer,
J. McCarty,
P. McKay,
Y. Minami,
H. Mociková,
E. Morra,
J. Muñoz,
H. Nagai,
O. O'connor,
Stephen Samuel Opat,
R. Pettengell,
A. Pezzutto,
M. Pfreundschuh,
A. Pluta,
P. Porcu,
H. Quach,
A. Rambaldi,
William E. P. Renwick,
Ruben Reyes,
A. Izquierdo,
J. Ruan,
C. Rusconi,
G. Salles,
A. Santoro,
J. Sarriera,
K. Savage,
H. Shibayama,
C. Suh,
A. Sureda,
M. Tanimoto,
M. Taniwaki,
H. Tilly,
M. Trněný,
L. Trumper,
N. Tsukamoto,
U. Vitolo,
J. Walewski,
E. Weidmann,
M. Wilhelm,
M. Witzens‐Harig,
A. Yacoub,
Kazuhito Yamamoto,
S. Yoon,
H. Yun,
J. Zain
|
9 |
2019 |
9
🐜
|
|
🐜
|
Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model.
9 auth.
Yan Zhang,
Hui-Li Tan,
Jacob D Daniels,
Fereshteh Zandkarimi,
Hengrui Liu,
L. Brown,
...
K. Uchida,
O. O’Connor,
B. Stockwell
|
8 |
2019 |
8
🐜
|
|
🦁
|
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
15 auth.
O. O’Connor,
M. Heaney,
L. Schwartz,
S. Richardson,
Robert Willim,
Barbara Macgregor-Cortelli,
Tracey Curly,
C. Moskowitz,
C. Portlock,
S. Horwitz,
...
A. Zelenetz,
S. Frankel,
V. Richon,
P. Marks,
W. Kelly
|
8 |
2006 |
8
🦁
|
|
🦁
|
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
17 auth.
O. O’Connor,
S. Horwitz,
T. Masszi,
A. van Hoof,
P. Brown,
J. Doorduijn,
G. Hess,
W. Jurczak,
P. Knoblauch,
S. Chawla,
...
G. Bhat,
M. Choi,
J. Walewski,
K. Savage,
F. Foss,
L. F. Allen,
A. Shustov
|
8 |
2015 |
8
🦁
|
|
🐜
|
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
14 auth.
T. Kewalramani,
A. Zelenetz,
S. Nimer,
C. Portlock,
D. Straus,
A. Noy,
O. O’Connor,
D. Filippa,
J. Teruya-Feldstein,
A. Gencarelli,
...
J. Qin,
A. Waxman,
J. Yahalom,
C. Moskowitz
|
8 |
2004 |
8
🐜
|
|
🐜
|
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
15 auth.
A. Goy,
S. Bernstein,
B. Kahl,
B. Djulbegovic,
M. Robertson,
S. Vos,
E. Epner,
A. Krishnan,
J. Leonard,
S. Lonial,
...
S. Nasta,
O. O’Connor,
Hongliang Shi,
A. Boral,
R. Fisher
|
8 |
2009 |
8
🐜
|
